Neuren Pharmaceuticals Limited (ASX: NEU) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Neuren Pharmaceuticals Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Neuren Pharmaceuticals Limited (ASX: NEU)
Latest News
Share Gainers
Here are the top 10 ASX 200 shares today
Healthcare Shares
Macquarie predicts 12% upside for this ASX 200 healthcare stock
Share Gainers
Here are the top 10 ASX 200 shares today
Broker Notes
Brokers name 3 ASX shares to buy today
Broker Notes
Down 10% in a day! Why this ASX stock could now deliver market-beating returns
Earnings Results
Neuren Pharmaceuticals Q3 2025: Record DAYBUE sales fuel robust growth
Healthcare Shares
Bell Potter just upgraded the target price on ASX healthcare stock
Healthcare Shares
Which biotech's shares have hit a 12-month high on good news from the FDA?
Share Gainers
Why DroneShield, Larvotto, Neuren, and Zip shares are rising today
Share Market News
Neuren Pharmaceuticals earns FDA Fast Track for NNZ-2591 in PMS
Healthcare Shares
CSL shares fall on new Trump tariff hit
52-Week Highs
Life360 and Neuren Pharmaceuticals among 9 ASX 200 shares hitting multi-year highs
Frequently Asked Questions
-
No, Neuren Pharmaceuticals does not pay dividends at this time.
-
Neuren Pharmaceuticals Limited (ASX: NEU) listed on the ASX on 3 February 2005.
NEU ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited (ASX: NEU) is a biopharmaceutical company specialising in developing new therapies for neurodevelopmental disorders that emerge in early childhood and are characterised by impaired connections and signalling between brain cells.
In March 2023, the US Food and Drug Administration approved DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adults and children two years and older. Neuren's US partner Acadia Pharmaceuticals (NASDAQ: ACAD) holds a worldwide exclusive licence from Neuren for trofinetide. At this time, DAYBUE is the first and only drug approved for the treatment of Rett syndrome. Trofinetide has also demonstrated clinical benefit in a Phase 2 trial in treating Fragile X syndrome.
Neuren's second product NNZ-2591 is currently in Phase 2 clinical trials for the treatment of Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome, and Prader-Willi syndrome. The drug candidate has shown positive effects in mouse models of each syndrome and was successful in a Phase 1 clinical trial. The number of patients across these four disorders is estimated as five times the number of Rett syndrome patients. There are currently no drugs approved for these conditions, apart from growth hormone to treat some aspects of Prader-Willi.
Acadia Pharmaceuticals also holds a worldwide exclusive licence to develop and commercialise NNZ-2591 for Rett syndrome and Fragile X syndrome. Neuren retains worldwide rights to NNZ-2591 in all other indications.
